Peginterferon beta - Bolder BioTechnology

Drug Profile

Peginterferon beta - Bolder BioTechnology

Alternative Names: BBT-032; PegIFN-beta - Bolder BioTechnology; PegIFN-β - Bolder Biotechnology

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bolder BioTechnology
  • Class Interferons
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple sclerosis
  • Discontinued Cancer

Most Recent Events

  • 04 Dec 2017 Peginterferon beta is still in preclinical development for Multiple sclerosis in USA (Bolder Biotechnology pipeline, December 2017)
  • 04 Dec 2017 Discontinued - Preclinical for Cancer in USA (Parenteral) before November 2017 (Bolder Biotechnology pipeline, December 2017)
  • 04 Dec 2017 Bolder Biotechnology plans a clinical trial for Multiple sclerosis in 2018 (Bolder Biotechnology pipeline, December 22015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top